phrykt

Biodesix Inc (BDSX): who owns it and who trades it

As of Nov 16, 2026, BDSX insiders reported 12 open-market sales worth $104K and 7 purchases worth $4.1M in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Scott Hutton (CEO), with $62.8K. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Biodesix

From the latest filings

Overall: more buying than selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns BDSX

44 funds and institutions reported BDSX shares worth $92.1M at the end of Q2 2026, about 40% of the company. The largest holder is AIGH Capital Management LLC with 6.7%.

Funds and institutions (13F) 40%Everyone else 60%

10 largest owners, by share of the company

AIGH Capital Management LLC6.7%
Soleus Capital Management, L.P.5.8%
Telemark Asset Management, LLC4.8%
Aberdeen Group plc3.8%
Vanguard Capital Management LLC2.8%
Essex Investment Management Co LLC2.4%
Opaleye Management Inc.1.8%
Marshall Wace, LLP1.1%
Perceptive Advisors LLC1.1%
Jane Street Group, LLC0.9%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
AIGH Capital Management LLC678,3286.71%$15.3M-11%
Soleus Capital Management, L.P.585,9585.80%$13.2M+41%
Telemark Asset Management, LLC489,8244.85%$11MNo change
Aberdeen Group plc388,6393.84%$8.8M-15%
Vanguard Capital Management LLC284,1692.81%$6.4M+11%
Essex Investment Management Co LLC241,9152.39%$5.5M+83%
Opaleye Management Inc.180,0001.78%$4.1M-24%
Marshall Wace, LLP116,1991.15%$2.6M-18%
Perceptive Advisors LLC108,6941.08%$2.5MNew
Jane Street Group, LLC91,5060.91%$2.1M+239%
Two Sigma Investments, LP86,8240.86%$2M+92%
Legato Capital Management LLC81,3810.81%$1.8M+98%
Walleye Capital LLC74,4470.74%$1.7M+587%
Stempoint Capital LP70,0000.69%$1.6M-50%
Geode Capital Management, LLC67,6570.67%$1.5M+35%
Trexquant Investment LP57,9720.57%$1.3M-17%
Gsa Capital Partners LLP46,9890.46%$1.1M+19%
Perkins Capital Management Inc44,6180.44%$1M-0%
BlackRock, Inc.43,0260.43%$970K+76%
Blair William & Co41,5480.41%$937K+51%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, BDSX insiders reported $4.1M of open-market purchases and $104K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$4.1M
7 trades, 1 people
Sales, 12 months
$104K
12 trades, 5 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Nov 10, 2026
Filed Nov 12, 2026

Purchases and sales by month

$2.1M$2.1MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 10, 2026Jack W Schuler10% ownerPurchase100,000$10.02$1MForm 4
Aug 12, 2026Jack W Schuler10% ownerPurchase15,000$24.47$367KForm 4
Aug 11, 2026Jack W Schuler10% ownerPurchase13,700$24.01$329KForm 4
Aug 10, 2026Jack W Schuler10% ownerPurchase13,900$24.25$337KForm 4
Feb 23, 2026Scott HuttonCEOSale1,490$12.78$19KForm 4
Feb 23, 2026Chris VazquezChief Accounting OfficerSale211$12.78$2.7KForm 4
Feb 23, 2026Gary Anthony PestanoChief Development OfficeSale556$12.78$7.1KForm 4
Feb 23, 2026Kieran O'KaneChief Commercial OfficerSale535$12.78$6.8KForm 4
Feb 10, 2026Chris VazquezChief Accounting OfficerSale101$10.08$1KForm 4
Feb 10, 2026Scott HuttonCEOSale3,559$10.08$35.9KForm 4
Feb 10, 2026Kieran O'KaneChief Commercial OfficerSale584$10.08$5.9KForm 4
Feb 10, 2026Gary Anthony PestanoChief Development OfficeSale540$10.08$5.4KForm 4
Feb 10, 2026Robin Harper CowieCFOSale941$10.08$9.5KForm 4
Jan 26, 2026Jack W Schuler10% ownerPurchase20,000$11.80$236KForm 4
Jan 23, 2026Jack W Schuler10% ownerPurchase80,000$11.81$945KForm 4
Jan 22, 2026Jack W Schuler10% ownerPurchase82,465$10.96$904KForm 4
Jan 16, 2026Chris VazquezChief Accounting OfficerSale83$8.15$676Form 4
Jan 16, 2026Gary Anthony PestanoChief Development OfficeSale298$8.15$2.4KForm 4
Jan 16, 2026Scott HuttonCEOSale970$8.15$7.9KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Jack W Schuler10% owner$4.1M–Nov 10, 2026
Scott HuttonPresident & CEO, Director–$62.8KFeb 23, 2026
Gary Anthony PestanoChief Development Officer–$15KFeb 23, 2026
Kieran O'KaneChief Commercial Officer–$12.7KFeb 23, 2026
Robin Harper CowieCFO, Sec'y & Treasurer–$9.5KFeb 10, 2026
Chris VazquezChief Accounting Officer–$4.4KFeb 23, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

BDSX short interest

Low short interest. 1.9% of BDSX shares are sold short: about 1 share in 53. Over the last 12 reports the number of shares short went up 53%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 210,018 BDSX shares were sold short, 1.9% of the shares outstanding, up 0.2% from the report before. At the average daily volume of 85,505 shares, buying them all back would take about 2.5 trading days (days to cover).

Shares short, % of all shares

1.89%May 15Oct 302.25%

Days to cover

2.5May 15Oct 303.6

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026210,0181.89%+0%85,5052.5
Oct 15, 2026209,5041.99%+4%89,3252.4
Sep 30, 2026201,8491.91%-6%109,8411.8
Sep 15, 2026214,0062.03%-3%64,9933.3
Aug 31, 2026220,3832.09%+47%166,0581.3
Aug 14, 2026150,0851.42%-5%94,8161.6
Jul 31, 2026157,1871.49%-6%58,6742.7
Jul 15, 2026167,9701.66%+59%76,5332.2
Jun 30, 2026105,4271.04%+1%125,4901.0
Jun 15, 2026104,6661.04%-2%39,9192.6
May 29, 2026106,4631.05%-22%46,9232.3
May 15, 2026137,1961.36%-7%101,6311.4

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Biodesix company events

Biodesix filed 7 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026LeadershipIt was agreed that the employment of Kieran O’Kane, Chief Commercial Officer of Biodesix, Inc. would end effective November 2, 2026. Filing
  2. Nov 5, 2026ResultsReleased financial results. Filing
  3. Aug 5, 2026ResultsReleased financial results. Filing
  4. May 20, 2026VoteReported shareholder vote results. Filing
  5. May 4, 2026ResultsReleased financial results. Filing
  6. Feb 26, 2026ResultsReleased financial results. Filing
  7. Jan 12, 2026ResultsAmended an earlier report. Released financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Biodesix financials

Famous investors that hold BDSX

3 of the 50 well-known investors we track reported holding BDSX in their latest 13F filing. The largest position is Israel Englander's, worth $3.4M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 2026114,666$3.4M0.0%+696%
Ken Griffin · Citadel AdvisorsQ3 202634,259$1M0.0%New
Jim Simons · Renaissance TechnologiesQ3 202632,348$965K0.0%+13%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named BDSX in the last 120 days.

FiledHolderFormStake
Nov 12, 2026SCHULER JACK W13D/A22.3%
Nov 12, 2026SCHULER JACK W13D/A22.3%

Questions about Biodesix Inc (BDSX) stock

Who owns the most BDSX stock?

The largest reported owner of Biodesix Inc (BDSX) is AIGH Capital Management LLC, with 6.7% of the company. In total, 44 funds and institutions reported holding BDSX at the end of Q2 2026, together about 40% of the shares. See the largest owners.

Are BDSX insiders buying or selling?

In the last 12 months, BDSX insiders reported 7 open-market purchases worth $4.1M and 12 sales worth $104K. The latest trade was on Nov 10, 2026. See every trade.

What is the short interest in BDSX?

As of Oct 30, 2026, 210,018 BDSX shares were sold short, 1.9% of the shares outstanding, up 0.2% from the report before. At the average daily volume of 85,505 shares, buying them all back would take about 2.5 trading days (days to cover). See the history.

Which famous investors hold BDSX?

3 of the 50 well-known investors we track reported BDSX in their latest 13F filing, including Israel Englander, Ken Griffin, Jim Simons. The largest position is worth $3.4M. See all holders.

Executive pay

Biodesix's chief executive was paid a total of $2.2M for the year ended Dec 31, 2025, up 7% from $2.1M the year before. In the last 12 months, Biodesix's executives and directors bought no stock on the open market and sold $104K.

Chief executive, total pay$2.2MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$666KThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$985KThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.